LEWISVILLE, Texas--(BUSINESS WIRE)--
Orthofix International N.V., (NASDAQ:OFIX) (the Company) announced today
in collaboration with the Musculoskeletal Transplant Foundation (MTF)
the full market release of Trinity® ELITE™ Allograft with
Viable Cells and VersaShield™ Amniotic Membrane tissue forms through
both of its Spine Fixation and U.S. Extremity Fixation distribution
channels. Trinity ELITE provides the unique feature of being fully
moldable by the user, a key distinction of the proprietary technology
that MTF developed.
Orthofix Announces Full Market Release and Launch of Trinity ELITE (Photo: Business Wire)
Dr. Peter M. Shedden, MSc., M.D., FRCS(C), FACS, FAANS, of the Greater
Houston Neurosurgery Center in The Woodlands, Texas and a member of the
Company's medical education team, stated, "In my initial usage of
Trinity ELITE, I have been extremely satisfied with the ability to pack
more graft material into a disc space during a posterior lumbar
interbody fusion procedure, as well as posterior laterally. In addition,
this novel allograft represents a new option for surgeons who want to
apply a cell-based allograft to the lateral gutter and lay it flat along
the transverse process."
Orthofix President and Chief Executive Officer Brad Mason noted, "We are
very excited about the initial feedback from the early adopters, which
has been universally and extremely positive, as it confirms Trinity
ELITE overcomes current challenges in graft containment and handling of
cell-based tissue forms. Orthofix has long maintained its commitment to
co-developing and commercializing such exciting technology with MTF, and
we plan to continue being innovators in this space."
Chief Executive Officer of the Musculoskeletal Transplant Foundation
Bruce Stroever commented, "Over the last five years, the MTF/Orthofix
partnership has proven to be a successful endeavor providing a new,
viable cell tissue form to tissue recipients. We are pleased to release
our newest innovation, Trinity ELITE. Trinity ELITE is the first fully
moldable allograft with viable cells. This next generation allograft is
the first cell-based offering of its kind designed to provide an
enhanced handling experience and greatly improved graft containment
Trinity ELITE, a third generation allograft with viable cells, provides
surgeons with a unique alternative to autograft, the standard for bone
grafting. Trinity ELITE builds on the exemplary safety profile of more
than 75,000 Trinity Evolution® procedures. Trinity ELITE
offers an enhanced handling experience, while providing a viable
The full market release of Trinity ELITE includes the launch into both
spinal and extremity applications and is available in four different
Orthofix International N.V. is a diversified, global medical device
company focused on developing and delivering innovative orthopedic
solutions that drive value for patients, surgeons, and providers.
Orthofix's products are widely distributed around the world to surgeons
and patients via Orthofix's sales representatives and its subsidiaries,
and via collaborations with other leading orthopedic product companies.
In addition, Orthofix is collaborating on R&D activities with leading
research and clinical organizations such as the Musculoskeletal
Transplant Foundation, the Orthopedic Research and Education Foundation,
and Texas Scottish Rite Hospital for Children. For more information
about Orthofix, please visit www.orthofix.com.
About the Musculoskeletal Transplant Foundation
The Musculoskeletal Transplant Foundation, the nation's leading tissue
bank, changes lives by connecting donors with surgeons and transplant
recipients. As a non-profit service organization, MTF is dedicated to
providing quality tissue through a commitment to excellence in
education, research, recovery and care for recipients, donors and their
families. Since its inception in 1987, MTF has recovered tissue from
more than 100,000 donors and distributed over 5 million grafts for
transplantation. For more information, please visit MTF's website at www.mtf.org.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20130701005222/en/
Orthofix International N.V.
Mark Quick, 214-937-2924
of Investor Relations and Business Development
Source: Orthofix International N.V.
News Provided by Acquire Media